Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19.
Anne HollerbachNadine Müller-CallejaDenise PedrosaAntje CanisiusMartin F SprinzlTanja FalterHeidi RossmannMarc BodensteinChristian WernerIngo SagoschenThomas MünzelOliver SchreinerVisvakanth SivanathanMichael ReuterJohannes NiermannPeter R GalleLuc TeytonWolfram RufKarl J LacknerPublished in: Journal of thrombosis and haemostasis : JTH (2021)
COVID-19 patients rapidly expand B1a cells secreting pathogenic lipid-binding aPL with broad thrombotic and inflammatory effects. The association with markers of inflammation and coagulation, clinical severity, and mortality suggests a causal role of aPL in COVID-19-associated coagulopathy.